HCC-REAADTM is an in-vitro diagnostic intended for early detection of hepatocellular carcinoma using patented biomarker. Elevated levels of this biomarker were identified within hepatocellular carcinoma patients’ plasma. Internal research studies by Restalyst indicated that this patented biomarker produces better sensitivity than AFP.


About Hepatocellular Carcinoma


Hepatocellular Carcinoma (HCC)is the most common type of liver cancer. Majority of HCC is a result of priori viral hepatitis infection (Hepatitis B or C), metabolic toxins such as ethyl alcohol or aflatoxin. It was once prevalent only in Southeast Asia and Afica due to intake of aflatoxin contaminated food grains. However, increasing alcohol consumption is the rising cause of hepatocellular carcinoma in Europe and America.


Disease symptoms are often discovered at late stages, preventing the possibility of early treatment and recovery. Patients with cirrhosis and hepatitis B infection have higher risk of developing HCC. Currently, the recognized screening test for HCC is using Alpha-fetoprotein (AFP) blood test and ultrasound exam (every 6 to 12 months).


Although AFP is widely used for HCC screening, patients with early stages of HCC can have normal AFP levels. The levels of AFP can be increased from other cancers.

Statistics (Globocan 2012)

Worldwide – 6th most common cancer; 2nd cause of cancer-related death
Europe – 13th most common cancer, 7th cause of cancer-related death
Asia – 5th most common cancer; 2nd cause of cancer-related death